Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial - Rohaan, Maartje W.; Stahlie, Emma H. A.; Franke, Viola; Zijlker, Lisanne P.; Wilgenhof, Sofie; van der Noort, Vincent; van Akkooi, Alexander C. J.; Haanen, John B. A. G. (BMC cancer, 2022)
Keywords: Cancer therapies; Clinical trials; Combination therapy; Disease; Early metastatic; Herpes simplex; Immune checkpoint inhibitor; Immune checkpoint inhibitors; Immune response; Immunotherapy; Lymphocytes; Medical prognosis; Melanoma; Metastases; Metastasis; Monoclonal antibodies; Neoadjuvant; Nivolumab; Patients; PD-1 protein; Quality of life; Response rates; Seroconversion; Study Protocol; Surgery; Talimogene laherparepvec; Targeted cancer therapy; Toxicity; Tumors; Vaccines; Netherlands